Trial NCT02636582

Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer

This randomized phase II trial studies how well nelipepimut-S plus GM-CSF vaccine therapy or
sargramostim works in treating patients with breast cancer. Vaccines made from peptide or
antigen and/or a person's white blood cells mixed with tumor proteins may help the body build
an effective immune response to kill tumor cells that express breast cancer. It is not yet
known whether nelipepimut-S plus GM-CSF vaccine or sargramostim is more effective in treating
patients with breast cancer.

Intervention

Laboratory Biomarker Analysis, Nelipepimut-S Plus GM-CSF Vaccine, Sargramostim

Condition

Ductal Breast Carcinoma In Situ

Investigators

See list of participating sites